Spruce Biosciences offers a high-risk, high-reward opportunity as it advances TA-ERT, potentially the first disease-modifying therapy for MPS IIIB, toward FDA approval. TA-ERT demonstrated durable ...
Kim Jae-ho, a professor in the Department of Neurology at Hallym University Dongtan Sacred Heart Hospital, has been selected ...
Discusses Preliminary Phase II Results for SNT-4728 in Isolated REM Sleep Behavior Disorder July 5, 2026 11:30 PM ...
Early detection and treatment of congenital cerebral ventriculomegaly (CCV)—when a fetus's fluid-filled brain ventricles ...
Introduction Bronchopulmonary dysplasia (BPD) remains a major complication among extremely low gestational age (ELGA) infants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results